Retrophin Reports Second Quarter 2016 Financial Results
Second quarter revenues increased 38 percent year-over-year Sparsentan top-line data expected in third quarter of 2016 RE-024 efficacy trial expected to initiate in second half of 2016 SAN DIEGO, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: …